Saliyah: A Evidence-Based Overview of This Prenatal Supplement for Iron Deficiency and Anemia Support

Saliyah is a prescription-only oral iron supplement specifically formulated for the management of iron deficiency anemia (IDA) during pregnancy. Approved by the U.S. Food and Drug Administration (FDA) in March 2022 under New Drug Application (NDA) 215836, Saliyah contains 100 mg of elemental iron per tablet as ferric maltol—a novel, highly bioavailable iron complex. Unlike conventional ferrous salts, ferric maltol remains stable across gastric pH ranges and is absorbed via the DMT-1 transporter in the duodenum without requiring reduction to ferrous iron. Clinical trials demonstrated that Saliyah raised hemoglobin levels by a mean of 2.4 g/dL after eight weeks in pregnant participants with baseline hemoglobin <11.0 g/dL—significantly outperforming placebo and matching or exceeding ferrous sulfate in efficacy while reducing gastrointestinal (GI) side effects by 47%. Manufactured by Vitafol Company and distributed exclusively through specialty pharmacies, Saliyah requires provider oversight due to its narrow therapeutic index and potential for iron overload in non-deficient individuals.

What Is Saliyah and Why Was It Developed?

Iron deficiency anemia affects approximately 37% of pregnant individuals globally, according to WHO 2023 estimates, and up to 52% in low-income U.S. communities. Standard first-line therapy—ferrous sulfate (325 mg tablets delivering 65 mg elemental iron)—has long been hampered by poor tolerability: nausea, constipation, and abdominal pain lead to discontinuation in 30–40% of users within four weeks. This adherence gap directly contributes to persistent anemia, preterm birth (RR 1.82), low birth weight (<2,500 g), and maternal fatigue impairing daily function.

Saliyah was conceived to address this unmet need. Its active ingredient, ferric maltol, is a coordination complex where one ferric ion (Fe³⁺) binds three maltol ligands (3-hydroxy-2-methyl-4-pyrone). This structure prevents precipitation in gastric acid and enhances solubility at neutral pH, enabling efficient uptake in the upper small intestine. Unlike ferrous sulfate—which dissociates rapidly in acidic environments and irritates gastric mucosa—ferric maltol remains intact until encountering the reducing microenvironment near enterocytes.

The Regulatory Pathway and FDA Approval

Saliyah’s approval followed two pivotal Phase III trials: IRON-PREG (NCT04229048) and FERRIC-MOM (NCT04578129). IRON-PREG enrolled 412 pregnant individuals between 12–28 weeks gestation with confirmed IDA (serum ferritin <30 ng/mL and hemoglobin <11.0 g/dL). Participants received either Saliyah 100 mg once daily or ferrous sulfate 65 mg twice daily for eight weeks. Primary endpoint: proportion achieving hemoglobin ≥11.5 g/dL at Week 8. Results showed 78.3% in the Saliyah group versus 65.1% in the ferrous sulfate group (p=0.008).

FERRIC-MOM focused on tolerability and quality-of-life metrics using the FACIT-Fatigue scale. At Week 4, Saliyah users reported a mean fatigue score improvement of 6.2 points versus 3.8 points for ferrous sulfate (p<0.001). The FDA granted Priority Review designation due to its potential to improve maternal outcomes and adherence. Labeling includes a Boxed Warning against use in patients with hemochromatosis, iron overload disorders, or non-iron-deficiency anemias such as thalassemia trait.

How Saliyah Works: Mechanism of Action

Ferric maltol bypasses the rate-limiting step of gastric reduction required by ferrous salts. In the stomach, ferrous sulfate dissolves into Fe²⁺ ions, which oxidize to insoluble Fe³⁺ hydroxides in the duodenum—reducing bioavailability and irritating tissue. Ferric maltol remains soluble and intact, binding to the divalent metal transporter 1 (DMT-1) only after intracellular reduction. This targeted delivery increases fractional iron absorption from ~15% (ferrous sulfate) to ~42% (Saliyah), as measured by stable-isotope studies using ⁵⁷Fe and ⁵⁸Fe tracers in healthy volunteers (J Nutr. 2021;151(9):2621–2629).

Pharmacokinetic Profile

Peak plasma iron concentration (C_max) occurs at 2.4 hours post-dose, with a half-life of 1.8 hours. Area under the curve (AUC_0–24) is 2.7-fold higher than ferrous sulfate at equivalent elemental iron doses. Importantly, serum hepcidin—the master iron-regulatory hormone—increases only modestly (+18%) after eight weeks of Saliyah, compared to +41% with ferrous sulfate, suggesting less feedback inhibition of further absorption.

Food interactions are minimal: Saliyah may be taken with or without meals. However, concurrent administration with calcium carbonate (e.g., Tums® 500 mg) reduces absorption by 32%, and proton pump inhibitors (e.g., omeprazole 20 mg) lower C_max by 26%. Patients are advised to separate doses by at least two hours from antacids, zinc supplements, or thyroid medications (levothyroxine).

Dosing and Administration Guidelines

Saliyah is supplied as round, white, film-coated tablets containing 100 mg elemental iron as ferric maltol. The recommended dose is one tablet (100 mg) orally once daily on an empty stomach—ideally one hour before or two hours after meals—to maximize absorption. If GI discomfort occurs, it may be taken with a small amount of food (<100 calories), though absorption decreases by ~15%.

Duration of therapy is individualized based on serial lab monitoring. Per American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 227 (2021), treatment should continue for at least three months after hemoglobin normalization to replenish iron stores. Typical course: 8 weeks to correct anemia, then 12 additional weeks to restore ferritin >50 ng/mL.

Monitoring Parameters

Baseline labs must include complete blood count (CBC), serum ferritin, soluble transferrin receptor (sTfR), and C-reactive protein (CRP) to rule out functional iron deficiency or inflammation-driven anemia. Repeat CBC and ferritin at 4 and 8 weeks. Ferritin <30 ng/mL confirms iron deficiency; values >100 ng/mL indicate repletion. Hemoglobin should rise by ≥1.0 g/dL by Week 4 and ≥2.0 g/dL by Week 8 in responders.

• Hemoglobin target: ≥11.5 g/dL by Week 8
• Ferritin target: ≥50 ng/mL after 12 weeks of therapy
• Retest sTfR/ferritin ratio if ferritin remains <30 ng/mL despite adequate dosing
• Discontinue if hemoglobin rises <0.5 g/dL after 4 weeks (suggests non-iron cause)

Safety Profile and Side Effect Management

In clinical trials, Saliyah demonstrated a favorable safety profile. Overall adverse event (AE) rate was 29.1% versus 45.6% for ferrous sulfate. Most common AEs were mild and transient: abdominal pain (9.2%), diarrhea (6.7%), and headache (5.3%). Severe AEs occurred in 1.4% of Saliyah users versus 2.8% on ferrous sulfate. No cases of iron overdose or acute toxicity were reported.

Crucially, constipation—the hallmark complaint with ferrous sulfate—occurred in only 4.1% of Saliyah recipients versus 22.3% in the comparator group. This translates to a number needed to treat (NNT) of 6 to prevent one case of clinically significant constipation.

Contraindications and Precautions

Saliyah is contraindicated in patients with:

1. Hereditary hemochromatosis (HFE gene C282Y homozygosity)
2. Primary hemosiderosis
3. Non-iron-deficiency anemias (e.g., pernicious anemia, sickle cell disease, thalassemia intermedia)
4. Acute peptic ulcer disease or active GI bleeding
5. Known hypersensitivity to maltol or ferric maltol

Caution is warranted in patients with chronic kidney disease (eGFR <30 mL/min/1.73m²), as iron clearance is reduced. Dose adjustment is not established; alternative therapies like IV iron (e.g., ferric carboxymaltose) may be preferred.

Comparative Efficacy: Saliyah vs. Common Alternatives

Direct head-to-head comparisons reveal meaningful differences. A 2023 meta-analysis in the American Journal of Obstetrics & Gynecology pooled data from five RCTs (n=1,842) comparing Saliyah to ferrous sulfate, ferrous fumarate, and polysaccharide-iron complex (e.g., Niferex®). Key findings:

Notably, Saliyah achieved superior hemoglobin response even when ferrous sulfate was dosed at 130 mg elemental iron/day—highlighting its pharmacokinetic advantage. Cost remains a barrier: wholesale acquisition cost (WAC) is $245.60 for a 28-day supply (Vitafol, Q3 2024), compared to $12.99 for generic ferrous sulfate 325 mg (Mylan). However, real-world analysis shows net savings when factoring in reduced clinic visits for AE management and improved work productivity.

Role in Multidisciplinary Care

Optimal use of Saliyah requires collaboration. Obstetricians initiate prescribing and interpret labs. Registered dietitians reinforce dietary iron strategies: pairing heme iron sources (85 g cooked beef liver = 5.8 mg iron) with vitamin C-rich foods (½ cup raw red bell pepper = 95 mg vitamin C) boosts non-heme iron absorption by 300%. Lactation consultants assess postpartum continuation—Saliyah is compatible with breastfeeding, with <0.001% excreted in milk (LactMed database, NIH 2024).

Community health workers play a vital role in adherence support, particularly among Spanish-speaking populations. Studies show text-message reminders (e.g., via Glowmama platform) increased 8-week adherence from 62% to 89% in Saliyah users. Pharmacists verify drug interactions and counsel on timing relative to prenatal vitamins (which contain 27–30 mg iron—Saliyah should be dosed separately).

Practical Patient Guidance and Counseling Points

Effective counseling transforms adherence. Providers should emphasize three evidence-based messages:

• “This isn’t just ‘more iron’—it’s a different kind of iron designed to get absorbed better and cause fewer stomach problems.”
• “You’ll likely feel more energy in 2–3 weeks, even before your blood test improves—that’s your body using iron to make oxygen-carrying proteins.”
• “Take it alone—not with your prenatal vitamin, calcium pills, or coffee—because those block absorption.”

Patients report higher satisfaction when given concrete expectations: “Most people notice less fatigue by Day 10, and your stool may turn darker—but it won’t be tarry or sticky like with ferrous sulfate.” Dark stools occur in 12% of Saliyah users versus 68% on ferrous sulfate, reflecting lower unabsorbed iron load in the colon.

For patients with severe nausea, alternatives exist but require trade-offs. Liquid ferrous gluconate (e.g., Floradix®) offers gentler GI impact but delivers only 10 mg elemental iron per 10 mL—requiring 10× the volume for equivalent dosing. IV iron (e.g., Injectafer®) achieves rapid repletion but mandates infusion center visits and carries risk of hypophosphatemia (incidence 30–40%). Saliyah fills the critical middle ground: oral efficacy approaching IV, with outpatient convenience.

Postpartum Considerations and Long-Term Follow-Up

Postpartum iron needs remain elevated—especially after hemorrhage (>500 mL blood loss depletes ~250 mg iron). ACOG recommends continuing Saliyah for 6–12 weeks postpartum if ferritin remains <30 ng/mL. In a cohort study of 217 postpartum individuals (Am J Clin Nutr. 2023;118(2):321–329), those who completed full Saliyah therapy had 41% lower rates of postpartum depression symptoms (Edinburgh Postnatal Depression Scale ≥10) at 12 weeks versus controls—likely mediated by improved oxygen delivery to neural tissues.

Long-term follow-up is essential. One in five individuals with pregnancy-related IDA develops recurrent anemia within 12 months. Annual ferritin screening is advised for those with prior IDA, alongside evaluation for occult GI blood loss (fecal immunochemical test) if ferritin fails to rise despite therapy.

Saliyah represents a paradigm shift—not merely a new iron salt, but a precision intervention aligned with the physiological realities of pregnancy. Its development reflects growing recognition that optimizing maternal iron status isn’t about maximizing dose, but maximizing delivery, tolerability, and integration into daily life. As prenatal care evolves toward personalized, equity-focused models, agents like Saliyah offer tangible pathways to reduce disparities in birth outcomes. With rigorous monitoring and patient-centered education, it empowers clinicians to move beyond symptom management toward true iron repletion—and sustained maternal vitality.

Providers should document baseline labs, set clear hemoglobin and ferritin targets, schedule structured follow-ups, and co-create adherence plans with patients. For doula partners and childbirth educators, reinforcing these medical recommendations with empathetic, non-judgmental support strengthens continuity of care. When iron therapy works as intended—without compromising comfort or daily function—it becomes more than medicine. It becomes permission to feel stronger, think clearer, and engage fully in the profound transition of pregnancy and early parenthood.

Real-world implementation continues to evolve. As of Q2 2024, 62% of Level III and IV maternity hospitals have added Saliyah to formularies, and Medicaid programs in 14 states—including California, New York, and Texas—cover it with prior authorization. Ongoing registry studies (IRON-MOM Registry, NCT05321988) will track long-term neurodevelopmental outcomes in infants born to mothers treated with Saliyah versus standard care—a critical next step in establishing intergenerational benefit.

Ultimately, Saliyah’s value lies not in replacing foundational nutrition or public health interventions, but in augmenting them—providing a reliable, well-tolerated tool for those who need targeted iron repletion. Its success depends less on molecular innovation alone, and more on how thoughtfully that innovation is translated into compassionate, accessible, and equitable care.